Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

AgomAb Therapeutics N.V

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million

Details:

Agomab’s pipeline consists of its lead candidate AGMB-129, a gastrointestinal tract restricted ALK-5 inhibitor for the treatment of fibrostenotic Crohn’s disease that is currently being investigated in a Phase 1 clinical trial in healthy volunteers.

Lead Product(s): ORG-129

Therapeutic Area: Gastroenterology Product Name: AGMB-129

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: $114.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing July 13, 2022

ASK
US

Upload
your Pipeline Activity

Galapagos

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Galapagos Presents New Data from The SELECTION Phase 3 Program at The United European Gastroenterology Week (UEGW) 2021 Congress

Details:

Filgotinib, an orally administered, preferential JAK1 inhibitor, used in the induction and maintenance of remission in patients with Crohn’s disease (CD).

Lead Product(s): Filgotinib

Therapeutic Area: Gastroenterology Product Name: Jyseleca

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 04, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY